APLN hFc Chimera, Human
APLN HFc Chimera, Human

Immobilized APLN hFc Chimera, Human, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-APLN Antibody, hFc Tag with the EC50 of 40.4 ng/ml determined by ELISA.

APLN HFc Chimera, Human

APLN hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

APLN hFc Chimera, Human

Macrophages play key roles during cardiovascular diseases (CVD) and their related complications.Apelin (APLN) is a key molecule, whose roles during CVD have been documented previously. Therefore, it has been hypothesized that APLN may perform its roles via modulation of macrophages. Additionally, due to the widespread distribution of the CVD, more effective therapeutic strategies need to be developed to overcome the related complications.
Z05031
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
APLN (Gly23-Phe77)
Accession # Q9ULZ1		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized APLN hFc Chimera, Human at 1μg/ml (100μl/Well) on the plate can bind Biotinylated Anti­APLN Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 32.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 35-40 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS, 200mM Arginine (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • APLN HFc Chimera, Human
    • APLN HFc Chimera, Human

    Immobilized APLN hFc Chimera, Human, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-APLN Antibody, hFc Tag with the EC50 of 40.4 ng/ml determined by ELISA.

  • APLN HFc Chimera, Human
    • APLN HFc Chimera, Human

    APLN hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Macrophages play key roles during cardiovascular diseases (CVD) and their related complications.Apelin (APLN) is a key molecule, whose roles during CVD have been documented previously. Therefore, it has been hypothesized that APLN may perform its roles via modulation of macrophages. Additionally, due to the widespread distribution of the CVD, more effective therapeutic strategies need to be developed to overcome the related complications.
Synonyms Apelin;APJ endogenous ligand;APEL

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.